ALNA Shares Outstanding History
Below is a table of the ALNA shares outstanding history going back to 11/2/2017:

Date ALNA Shares Outstanding

Also see: ALNA Market Cap History
ALNA Historical Shares Outstanding:
+34.03% CAGR
ALNA Historical Shares Outstanding: +34.03% CAGR

Mouse over chart for data details
11/2/2017 ...5/7/2021
Allena Pharmaceuticals is a late-stage, clinical biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Co.'s main product candidate, reloxaliase, is an oral enzyme therapeutic that Co. is developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease (CKD) and end-stage renal disease. Co.'s second product candidate, ALLN-346, is for patients with hyperuricemia and gout in the setting of CKD. We show 18 historical shares outstanding datapoints in our coverage of ALNA's shares outstanding history.

Understanding the changing numbers of ALNA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ALNA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ALNA by allowing them to research ALNA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ALNA:
ALNA SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Allena Pharmaceuticals (ALNA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ALNY Shares Outstanding History
ALOG Shares Outstanding History
ALPN Shares Outstanding History
ALQA Shares Outstanding History
ALRN Shares Outstanding History
ALT Shares Outstanding History
ALXN Shares Outstanding History
AMAG Shares Outstanding History
AMDA Shares Outstanding History
AMED Shares Outstanding History
More Healthcare companies »


ALNA Shares Outstanding History | | Copyright © 2017 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.